President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Adult ClinicPediatricsEye CareBillingInfo for Healthcare ProfessionalsDiabetes Information & Resources
50-Year Medalist StudyClinical Research
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternational
Give NowGet InvolvedEventsTributes & Special OccasionsCorporate & Foundation EngagementLegacy GivingWays to GivePhilanthropy TeamPublications

Management of Type 2 Diabetes in People with Renal Impairment: Clinical Perspectives

Activity Description

Management of Type 2 Diabetes in People with Renal Impairment: Clinical Perspectives

Bethesda, Maryland
Tuesday, February 05, 2013
6:45 PM - 9:00 PM
Statement of Need

Renal dysfunction is often a comorbidity of type 2 diabetes and managing it and its clinical impact is a challenge for many clinicians. Too often renal dysfunction goes undetected when early intervention has the potential to slow or prevent its progression. Glycemic treatment adjustments may also be indicated because of reduced renal function, but are not always initiated. Primary care providers are on the front lines of care for many people with type 2 diabetes, and are perfectly positioned for timely identification of issues and intervention aimed at improving patient health and quality of life.

This is a must-attend symposium for the primary care clinician wishing to develop skills and learn methods for early recognition of, and intervention for, renal impairment in their patients with type 2 diabetes. In addition to highlighting methods to optimize glycemic control and reach target levels in the context of renal dysfunction, the symposium will give participants the opportunity to work through a case vignette designed to enhance their clinical understanding and build practical skills for assessing renal function and initiating therapy while concurrently adapting diabetes treatment. Upon completion of this activity, participants will have the opportunity for follow-up learning activities and practice support through the Joslin Professional Education Continuum (JPECTM) platform.

Target Audience

This certified live activity has been developed for primary care providers and their clinical and office staff. There is no fee to attend this live activity. However, space is limited, and reservations will be accepted on a first-come, first-served basis. Only clinicians can be admitted. Guests who are not clinicians cannot be accommodated.

6:00 PM Registration and Dinner
6:45 Welcome, Opening Remarks, and Introduction to JPEC
7:00 Renal Disease and Diabetes: Implications and Interventions
7:30 When Renal Impairment Accompanies Diabetes: Impact on Glycemic Control
8:00 Case Vignette: Renal Disease and Diabetes as Comorbidities
8:25 Postprogram Assessment and Orientation to Follow-up Learning on JPEC
8:35 Question and Answer Session
8:45 Concluding Remarks and Adjournment
Learning Objectives

Participants will be provided with clinically relevant, evidence-based information.
Upon completion of this activity, participants should be able to:

  • Explain the impact of renal impairment on the design and implementation of antidiabetes medication therapy for type 2 diabetes
  • Design and advance an antidiabetes medication treatment program for type 2 diabetes in the presence of reduced renal function
  • Implement strategies in the practice that can be used to slow the progression of renal dysfunction in someone with diabetes

This activity has been designed to address and encourage the following IOM/ACGME Competencies:

  • Medical knowledge
  • Patient care
  • Evidence-based practice

Speakers for this activity will be drawn from the distinguished faculty listed below.*

Paul S. Jellinger, MD, MACE
Professor of Clinical Medicine
University of Miami
Miami, FL
Past President, American College of Endocrinology
American Association of Clinical Endocrinologists (AACE)

Mark E. Molitch, MD
Martha Leland Sherwin Professor of Endocrinology
Division of Endocrinology, Metabolism and Molecular Medicine
Northwestern University Feinberg School of Medicine
Chicago, IL

Robert C. Stanton, MD
Associate Professor of Medicine
Harvard Medical School
Chief of Nephrology
Joslin Diabetes Center
Boston, MA

Mark E. Williams, MD, FACP, FASN
Associate Professor of Medicine
Harvard Medical School
Co-Director of Dialysis
Beth Israel Deaconess Medical Center
Senior Staff Physician
Joslin Diabetes Center
Boston, MA

*Faculty list subject to change

Accreditation and Designation of Credit

Joslin Diabetes Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Joslin Diabetes Center designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits. TM Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CME live activity was planned and produced in accordance with ACCME Essentials. Health professionals not eligible for continuing medical education credit will receive a certificate of participation that they may submit to their state licensing board for credit.

Disclosure Policy

It is the policy of Joslin Diabetes Center to ensure fair balance, independence, objectivity, and scientific rigor in all activities. All faculty participating in CME activities sponsored by Joslin Diabetes Center are required to present evidence-based data, identify and reference off-label product use, and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials.

This activity is supported by educational grants from Abbott Diabetes Care, Reata Pharmaceuticals Inc, and BI/Lilly

Page last updated: June 21, 2018